Literature DB >> 1951584

A 20-year series of orbital exenteration.

P S Levin1, J J Dutton.   

Abstract

We reviewed patient records of 99 consecutive orbital exenterations performed between 1969 and 1988. Patients ranged in age from 2 to 86 years (mean, 55.9 years). Classification of cases on histopathologic criteria showed 32 exenterations were performed for squamous cell carcinoma originating in the paranasal sinus (13), skin (12), conjunctiva (six), and lacrimal sac (one). Orbital exenteration was performed for treatment of other epithelial malignancy in basal cell carcinoma (eight), sebaceous carcinoma (six), adenoid cystic carcinoma (five), undifferentiated carcinoma (four), adenocarcinoma (two), intraepithelial carcinoma of the conjunctiva (two), benign mixed tumor (one), and transitional cell carcinoma (one). Exenterations were performed for melanoma of the conjunctiva (ten), nasosinus (three), skin (two), orbit (two), and choroid (one). Exenterations were also performed as treatment for mucormycosis (five), meningioma (three), fibrosarcoma (two), rhabdomyosarcoma (two), hemangiopericytoma (two), orbital cellulitis (one), fibrous histiocytoma (one), schwannoma (one), lymphangioma (one), benign lymphoepithelial lesion (one), and undifferentiated malignancy (one).

Entities:  

Mesh:

Year:  1991        PMID: 1951584     DOI: 10.1016/s0002-9394(14)76848-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Total regression of extensive conjunctival intraepithelial neoplasia with superficial corneal invasion treated with topical mitomycin C 0.02%.

Authors:  Marta Calatayud; Josep Badal; Laia Bisbe; Sara Martin; Javier Puig
Journal:  BMJ Case Rep       Date:  2009-12-03

2.  Orbital exenteration: surgical and reconstructive strategies.

Authors:  C Mohr; J Esser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-05       Impact factor: 3.117

3.  Orbital exenteration: a 13 year Manchester experience.

Authors:  I Rahman; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

4.  Multicentric sebaceous gland carcinoma of the lid?

Authors:  H von Below; G E Rose; A C McCartney; J E Wright
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

5.  Mortality following exenteration for malignant tumours of the orbit.

Authors:  I Rahman; A Maino; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

6.  Clinicopathological profile of orbital exenteration: 14 years of experience from a tertiary eye care center in South India.

Authors:  Mohammad Javed Ali; Aditi Pujari; Tarjani Vivek Dave; Swathi Kaliki; Milind N Naik
Journal:  Int Ophthalmol       Date:  2015-08-07       Impact factor: 2.031

7.  Exenteration for benign orbital disease.

Authors:  G E Rose; J E Wright
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

8.  Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.

Authors:  Kai Yuen Wong; Kate Fife; John T Lear; Richard D Price; Amer J Durrani
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-07-21

9.  Factors related to survival outcomes following orbital exenteration: a retrospective, comparative, case series.

Authors:  Orapan Aryasit; Passorn Preechawai; Chakree Hirunpat; Orasa Horatanaruang; Penny Singha
Journal:  BMC Ophthalmol       Date:  2018-07-28       Impact factor: 2.209

10.  Orbital Exenteration: A 23-year Report.

Authors:  Abolfazl Kasaee; Bahram Eshraghi; Shahbaz Nekoozadeh; Kambiz Ameli; Motahareh Sadeghi; Mansooreh Jamshidian-Tehrani
Journal:  Korean J Ophthalmol       Date:  2019-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.